You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

New Horizons in ADHD

  • Authors: Ann C. Childress, MD; Margaret H. Sibley, PhD; Gregory W. Mattingly, MD
  • CME / ABIM MOC / CE Released: 7/5/2022
  • Valid for credit through: 7/5/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), pediatricians, nurses, nurse practitioners (NPs), and physician assistants (PAs).

The goal of this activity is that learners will be better able to improve the screening, diagnosis, and treatment of attention-deficit hyperactivity disorder (ADHD).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging and novel interventions for treatment of ADHD 
  • Have greater competence related to
    • Managing ADHD in patients with common psychiatric comorbidities 
    • Supporting and facilitating successful transition of mental healthcare for patients with ADHD as they develop into adults
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into ADHD care 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships. Disclosures for additional planners can be found here.


Faculty

  • Ann C. Childress, MD

    President
    Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada

    Disclosures

    Ann C. Childress, MD, has the following relevant financial relationships:
    Consultant or advisor for: Cingulate; Corium; KemPharm; Noven; Otsuka; Supernus
    Speaker or member of speakers bureau for: Corium; Ironshore; Shire; Takeda; Tris
    Research funding from: Adlon; Allergan; Akili; Arbor; Emalex; KemPharm; Otsuka; Purdue; Sunovion; Supernus

  • Margaret H. Sibley, PhD

    Associate Professor
    Psychiatry and Behavioral Sciences
    University of Washington School of Medicine
    Seattle, Washington

    Disclosures

    Margaret H. Sibley, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Supernus Pharmaceuticals

  • Gregory W. Mattingly, MD

    Associate Clinical Professor
    Washington University School of Medicine
    President, Midwest Research Group
    President-Elect
    APSARD - American Professional Society for ADHD and Related Disorders
    St. Louis, Missouri

    Disclosures

    Gregory W. Mattingly, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Acadia; Alkermes; Axsome; Eisai; Ironshore; Intra-Cellular; Janssen; Lundbeck; Neos; Neurocrine; Otsuka; Redax; Roche; Rhodes; Sage; Shire; Sunovion; Supernus; Takeda; Teva; Trispharma
    Speaker or member of speakers bureau for: AbbVie; Alkermes; Eisai; Janssen; Lundbeck; Neurocrine; Otsuka; Sunovion; Supernus; Takeda; Trisphama
    Contracted researcher for: AbbVie; Acadia; Alkermes; Avanir; Axsome; Boehringer Ingelheim; Emalex; Janssen; Medgenics; NLS1 Pharma AG; Redax; Roche; Sage; Shire; Sunovion; Supernus; Takeda; Teva

Editor

  • Faisal Islam, MD, MBA

    Medical Education Director, Medscape, LLC

    Disclosures

    Faisal Islam, MD, MBA, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

New Horizons in ADHD

Authors: Ann C. Childress, MD; Margaret H. Sibley, PhD; Gregory W. Mattingly, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/5/2022

Valid for credit through: 7/5/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Innovations in ADHD: Pharmacologic and Nonpharmacologic Advances

Breakthroughs in ADHD treatments for 2022
Gregory B. Mattingly, MD

Case Conundrums in ADHD: Managing Comorbid Psychiatric Disorders

Addressing overlapping symptom presentations
Ann C. Childress, MD

Supporting Patients with ADHD Through the Transition to Independence

How to leverage engagement strategies and build a rewards system
Margaret H. Sibley, PhD
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to improve the screening, diagnosis, and treatment of attention-deficit hyperactivity disorder (ADHD).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.